Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actinium Pharmaceuticals, Inc. on March 24, 2014. The report covers the specific event of the Company's up-listing to the NYSE MKT exchange, announced via a press release issued on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance data.
Material Changes
The primary material change reported is the Company's transition to trading on the NYSE MKT exchange. No financial comparisons to prior periods are included in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the up-listing. The filing does not contain specific guidance, risk factors, contingencies, or unusual items beyond the exchange listing event.
Key Facts for Investor Verification
- Confirm the effective date of trading on the NYSE MKT exchange.
- Verify the ticker symbol assigned to the Company upon up-listing.
- Review the attached press release (Exhibit 99.1) for details on the listing criteria met.